16 February 2021
New study finds CANTAB is sensitive to very early cognitive changes in premanifest Huntington’s disease
Dr. Christelle Langley, postdoctoral Research Associate at the University of Cambridge School of Clinical Medicine shared the role that CANTAB played in her latest publication: Fronto-striatal circuits for cognitive flexibility in far from onset Huntington’s Disease: Evidence from the Young Adult Study
2 February 2021
We recently spoke with Dr Lisa Evju Hauger to discuss the impact CANTAB had on her research into exploring executive function in relation to long-term anabolic androgenic steroids (AAS) use and dependence.
15 December 2020
In times of a pandemic, being able to deliver cognitive tests remotely becomes even more relevant and can prevent the interruption of clinical studies: but are cognitive assessments comparable in the clinic and the home? New research, published in the Journal of Medical Internet Research, demonstrates that performance on the Cambridge Neuropsychological Test Automated Battery (CANTABTM) is broadly comparable when delivered unsupervised online or in-person in the laboratory.
9 December 2020
Nearly a year on from the first outbreak of COVID-19, we still have a lot to learn about how the virus works and affects our health. In this article Operational Scientist, Iona Pickett, explores our current understanding of the neuropsychological consequences of COVID-19, in particular the impact on cognitive function.
4 December 2020
Digital health expert Dr Jordan Brayanov from Takeda Pharmaceuticals shares his lessons learned delivering virtual trials during Covid-19 and predictions on what’s next for the industry.
16 November 2020
Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI.
Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1